Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2020, Vol. 40 Issue (6): 10-19    DOI: 10.13523/j.cb.1912021
研究报告     
Ozanimod(RPC1063)在少突胶质前体细胞分化中的作用和机制 *
张莹1,2,孔祥熙2,侯琳1,王树坤2,**(),袁增强1,2,**()
1 青岛大学基础医学院 青岛 266071
2 军事医学研究院军事认知与脑科学研究所 北京 100850
Role and Mechanism of Ozanimod (RPC1063) in Oligodendrocyte Precursor Cell Differentiation
ZHANG Ying1,2,KONG Xiang-xi2,HOU Lin1,WANG Shu-kun2,**(),YUAN Zeng-qiang1,2,**()
1 School of Basic Medicine, Qingdao University, Qingdao 266071, China
2 Institute of Military Cognition and Brain Sciences, Academy of Military Medical Sciences, Beijing 100850, China
 全文: PDF(2116 KB)   HTML
摘要:

目的 研究Ozanimod(RPC1063)在少突胶质前体细胞(oligodendrocyte precursor cell, OPC)分化中的作用,并初步探讨其分子机制。方法 利用免疫吸附法直接分离OPC诱导培养,使用免疫荧光染色、实时荧光定量PCR(quantitative real time-PCR, qRT-PCR)对细胞进行鉴定。qRT-PCR法检测大脑皮层发育、OPC分化过程中的S1pr家族基因mRNA水平变化。OPC经不同浓度RPC1063处理后,使用MTT法、ATP细胞活性检测法、免疫荧光染色、qRT-PCR和Western blot检测RPC1063对OPC分化细胞数目、mRNA或蛋白水平的影响。结果 利用免疫吸附法可获得高纯度的OPC;而MTT、ATP检测结果显示在0、0.1、1、5、50、100nmol/L浓度下,RPC1063对细胞活性无明显影响。进一步研究发现,RPC1063处理OPC后,O4、MBP阳性细胞形态舒展,MBP蛋白表达量增加,OPC分化相关基因MbpMagSox10Cnp的mRNA水平增加。机制上,少突胶质细胞系Oli-neu或OPC经RPC1063处理5min后,AKT-mTOR信号通路相关蛋白p-AKT、p-mTOR、p-4EBP1显著增加,OPC经RPC1063处理48h后,p-AKT、p-mTOR蛋白水平增加;而抑制mTOR活性,RPC1063作用减弱。结论 RPC1063通过AKT-mTOR信号通路促进少突胶质前体细胞的分化。

关键词: Ozanimod (RPC1063)少突胶质前体细胞脱髓鞘疾病    
Abstract:

Objective: This study aims to pinpoint the role of Ozanimod (RPC1063) in the differentiation of oligodendrocyte precursor cell (OPC) and investigate the underlying molecular mechanism.Methods: OPC was directly isolated by immune adsorption and indentified through immunofluorescence and quantitative real time-PCR. Firstly, the mRNA level of S1pr family genes was detected by qRT-PCR during the cerebral cortex development and OPC differentiation. Then, viability of OPC treated with different concentrations of RPC1063 was measured by MTT assay and ATP cell viability assay. Moreover, by means of immunofluorescence, qRT-PCR, and Western blot, we analysed the effects of RPC1063 on the differentiation rate of OPC, and the mRNA or protein level of OPC-differentiation associated genes.Results: High purity of OPC could be obtained by the method of immune adsorption from the cortex of mice. There was no significant effect of RPC1063 on cell viability at concentrations of 0, 0.1, 1, 5, 50, 100nmol/L. Additionally, up-regulation of O4+ or MBP+ cells, and protein level of MBP and mRNA level of Mbp, Sox10, Cnp, or Plp were observed in OPC treated with RPC1063. Moreover, in RPC1063-treated Oli-neu cells, the protein levels of pAKT, p-mTOR and p-4EBP1 were significantly increased at 5min. Besides, the proteins related to p-AKT-mTOR signaling pathway were also significantly increased in OPC. The promotion of RPC1063 on OPC differentiation was weakened by the inhibition of mTOR pathway.Conclusion: RPC1063 promotes the differentiation of oligodendrocyte precursor cell through activating the AKT-mTOR signaling pathway.

Key words: Ozanimod (RPC1063)    Oligodendrocyte precursor cell    Demylinating diseases
收稿日期: 2019-12-14 出版日期: 2020-06-23
ZTFLH:  Q291  
基金资助: * 国家自然科学基金(81630029);国家自然科学基金(31600946)
通讯作者: 王树坤,袁增强     E-mail: wangshukun954215@163.com;zqyuan@bmi.ac.cn
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
张莹
孔祥熙
侯琳
王树坤
袁增强

引用本文:

张莹,孔祥熙,侯琳,王树坤,袁增强. Ozanimod(RPC1063)在少突胶质前体细胞分化中的作用和机制 *[J]. 中国生物工程杂志, 2020, 40(6): 10-19.

ZHANG Ying,KONG Xiang-xi,HOU Lin,WANG Shu-kun,YUAN Zeng-qiang. Role and Mechanism of Ozanimod (RPC1063) in Oligodendrocyte Precursor Cell Differentiation. China Biotechnology, 2020, 40(6): 10-19.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.1912021        https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I6/10

Gene Forward primer Reverse primer
S1pr1 ATGGTGTCCACTAGCATCCC CGATGTTCAACTTGCCTGTGTAG
S1pr3 ACTCTCCGGGAACATTACGAT CAAGACGATGAAGCTACAGGTG
S1pr4 GTCAGGGACTCGTACCTTCCA GATGCAGCCATACACACGG
S1pr5 GCTTTGGTTTGCGCGTGAG GGCGTCCTAAGCAGTTCCAG
Pdgfrα ACACGTTTGAGCTGTCAACC CCCGACCACACAAGAACAGG
Olig2 GGGAGGTCATGCCTTACGC CTCCAGCGAGTTGGTGAGC
Mbp GACCATCCAAGAAGACCCCAC GCCATAATGGGTAGTTCTCGTGT
Cnp TTTACCCGCAAAAGCCACACA CACCGTGTCCTCATCTTGAAG
Mag CTGCCGCTGTTTTGGATAATGA CATCGGGGAAGTCGAAACGG
Sox10 ACACCTTGGGACACGGTTTTC TAGGTCTTGTTCCTCGGCCAT
β-actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT
表1  qRT-PCR引物
图1  OPC的分离和鉴定
图2  S1PR家族在大脑发育和OPC分化中的表达
图3  RPC1063对OPC活性和表型的影响
图4  RPC1063促进OPC分化
图5  RPC1063促进OPC分化的机制
[1] Rosenthal J F, Hoffman B M, Tyor W R . CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. J Investig Med, 2020,68(2):321-330.
pmid: 31582425
[2] Vega-Riquer J M, Mendez-Victoriano G, Morales-Luckie R A , et al. Five decades of cuprizone, an updated model to replicate demyelinating diseases. Curr Neuropharmacol, 2019,17(2):129-141.
pmid: 28714395
[3] Hartley M D, Banerji T, Tagge I J , et al. Myelin repair stimulated by CNS-selective thyroid hormone action. JCI Insight, 2019,4(8):e126329.
[4] Akaishi T, Nakashima I . Efficiency of antibody therapy in demyelinating diseases. Int Immunol, 2017,29(7):327-335.
[5] Höftberger R, Lassmann H . Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol, 2017,145:263-283.
[6] Franklin R J, Ffrench-Constant C . Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci, 2008,9(11):839-855.
pmid: 18931697
[7] Franco P G, Silvestroff L, Soto E F , et al. Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. Exp Neurol, 2008,212(2):458-467.
doi: 10.1016/j.expneurol.2008.04.039 pmid: 18572165
[8] Mi S, Miller R H, Tang W , et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol, 2009,65(3):304-315.
[9] Brinkmann V . Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther, 2007,115(1):84-105.
[10] Martin R, Sospedra M . Sphingosine-1 phosphate and central nervous system. Curr Top Microbiol Immunol, 2014,378:149-170.
doi: 10.1007/978-3-319-05879-5_7 pmid: 24728597
[11] Zhang J, Zhang Z G, Li Y , et al. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis. Neurobiol Dis, 2015,76:57-66.
[12] Khatri B O . Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord, 2016,9(2):130-147.
[13] Cohen J A, Barkhof F, Comi G , et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med, 2010,362(5):402-415.
doi: 10.1056/NEJMoa0907839 pmid: 20089954
[14] Taylor Meadows K R, Steinberg M W, Clemons B , et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS One, 2018,13(4):e0193236.
doi: 10.1371/journal.pone.0193236 pmid: 29608575
[15] Cohen J A, Arnold D L, Comi G , et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol, 2016,15(4):373-381.
[16] Cohen J A, Comi G, Arnold D L , et al. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Mult Scler, 2019,25(9):1255-1262.
pmid: 30043658
[17] Cohen J A, Comi G, Selmaj K W , et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol, 2019,18(11):1021-1033.
pmid: 31492652
[18] Rasche L, Paul F . Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opin Pharmacother, 2018,19(18):2073-2086.
[19] Chaudhry B Z, Cohen J A, Conway D S . Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics, 2017,14(4):859-873.
doi: 10.1007/s13311-017-0565-4 pmid: 28812220
[20] Wang L, Yang H, Zang C , et al. CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis. Neurobiol Dis, 2020,134:104630.
doi: 10.1016/j.nbd.2019.104630 pmid: 31678404
[21] Varas R, Ortiz F C . Neuroinflammation in demyelinating diseases: oxidative stress as a modulator of glial cross-talk. Curr Pharm Des, 2019,25(45):4755-4762.
doi: 10.2174/1381612825666191216125725 pmid: 31840603
[22] Qiu K, He Q, Chen X , et al. Pregnancy-related immune changes and demyelinating diseases of the central nervous system. Front Neurol, 2019,10:1070.
doi: 10.3389/fneur.2019.01070 pmid: 31649614
[23] Scott F L, Clemons B, Brooks J , et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. British Journal of Pharmacology, 2016,173(11):1778-1792.
[24] Wong K K . Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat Anticancer Drug Discov, 2009,4(1):28-35.
doi: 10.2174/157489209787002461 pmid: 19149686
[25] Sun X, Liu Y, Liu B , et al. Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse. Exp Neurol, 2012,237(2):304-311.
pmid: 22836144
[1] 谈沛林,张莹,张竣,高笑,王树坤,侯琳,袁增强. 二甲双胍(Metformin)在少突胶质前体细胞分化中的作用和机制*[J]. 中国生物工程杂志, 2021, 41(9): 1-9.
[2] 李真, 刘兆雨, 徐丹, 陈婷, 孟赞, 唐勇, 彭彦. 星形胶质细胞通过CX47促进少突胶质前体细胞增殖[J]. 中国生物工程杂志, 2015, 35(12): 21-29.